Compound

Nifedipine

ATC Index

Nifedipine: Calcium Channel Blocker for Hypertension

Learn about Nifedipine, a calcium channel blocker used to treat hypertension and angina. Discover dosage, side effects, and drug interactions.

Nifedipine calcium channel blocker antihypertensive medication ATC C08 hypertension treatment angina pectoris cardiac medication vasodilator drug
ATC Code: C08
Last updated: Feb 23, 2026
Medical Reference

Looking to order Nifedipine?

Browse our catalog for available pharmaceutical products and competitive pricing.

View Products

What is Nifedipine?

Nifedipine is a potent calcium channel blocker belonging to the dihydropyridine class of antihypertensive medications. It is classified under ATC code C08, which encompasses calcium channel blockers used in cardiovascular medicine. Nifedipine was first synthesized in 1972 and has since become one of the most widely prescribed medications for managing hypertension and angina pectoris worldwide.

This pharmaceutical compound works by inhibiting the influx of calcium ions into vascular smooth muscle cells and cardiac myocytes, leading to vasodilation and reduced cardiac workload. Nifedipine is available in multiple formulations, including immediate-release tablets, sustained-release formulations, and extended-release preparations, allowing for flexible dosing schedules tailored to individual patient needs.

The drug is known for its rapid onset of action, particularly in immediate-release forms, making it valuable in acute hypertensive situations. Its cardiovascular benefits extend beyond simple blood pressure reduction, as it provides additional therapeutic advantages in managing various cardiac conditions and improving overall cardiovascular health.

⚙️ Mechanism of Action

Nifedipine exerts its therapeutic effects primarily through selective inhibition of voltage-dependent L-type calcium channels. By blocking these calcium channels, the medication prevents calcium-mediated contraction of vascular smooth muscle and cardiac tissue. This mechanism results in arterial vasodilation, decreased peripheral vascular resistance, and reduced afterload on the heart. The drug demonstrates particular affinity for vascular smooth muscle compared to cardiac myocardium at therapeutic doses, which helps minimize negative cardiac inotropic effects while maximizing blood pressure-lowering benefits.

  • Blocks L-type calcium channels in vascular smooth muscle cells, preventing calcium influx and muscle contraction
  • Causes arterial vasodilation, leading to reduced peripheral vascular resistance and decreased blood pressure
  • Reduces cardiac afterload by lowering systemic vascular resistance, improving myocardial oxygen supply-demand ratio
  • Has coronary vasodilatory properties that improve blood flow to the heart muscle, particularly beneficial in angina management
  • Demonstrates minimal effects on cardiac conduction at therapeutic doses due to selective vascular targeting

🏥 Medical Uses & Indications

Nifedipine is a versatile cardiovascular medication with established efficacy in multiple clinical conditions. Its primary use centers on blood pressure management and angina relief, though its applications extend to various other cardiovascular and non-cardiovascular conditions. Healthcare providers may select Nifedipine as monotherapy or in combination with other antihypertensive agents, depending on individual patient characteristics and comorbidities.

Primary Indications

  • Essential hypertension: Used as monotherapy or in combination with other antihypertensive agents for chronic blood pressure management
  • Angina pectoris: Both chronic stable angina and vasospastic (Prinzmetal's) angina management, providing symptom relief and reducing anginal episodes
  • Hypertensive urgency: Immediate-release formulations used for acute blood pressure reduction in urgent clinical settings
  • Post-myocardial infarction: Employed to reduce cardiac workload and improve myocardial perfusion during cardiac rehabilitation phases
  • Left ventricular dysfunction: Helps improve cardiac output and reduce afterload in certain heart failure scenarios
  • Raynaud's phenomenon: Reduces frequency and severity of vasospastic episodes in digits

Secondary / Off-label Uses

  • Preterm labor: Extended-release formulations used to inhibit uterine contractions and prolong pregnancy duration
  • Hypertensive crisis management: Immediate-release formulations for rapid blood pressure control in emergency situations
  • Severe migraine headaches: May reduce migraine frequency and severity in select patients
  • Esophageal spasm: Helps reduce painful esophageal contractions in patients with achalasia or related conditions

💊 Dosage & Administration

Nifedipine dosing is highly individualized and depends on the specific formulation, clinical indication, patient age, renal and hepatic function, and concurrent medications. Immediate-release formulations provide rapid onset but require more frequent dosing, while extended-release preparations offer once-daily or twice-daily convenience with steadier drug levels. Initial doses are typically conservative to minimize adverse effects, with gradual titration based on therapeutic response and tolerability.

IndicationTypical DoseFrequencyRoute
Essential Hypertension (Extended-release)30-90 mgOnce dailyOral
Angina Pectoris (Extended-release)30-90 mgOnce dailyOral
Hypertensive Urgency (Immediate-release)10-20 mgEvery 20-30 minutes as neededOral or sublingual
Vasospastic Angina (Immediate-release)10-20 mgThree times dailyOral

Important: Always follow your prescriber's instructions. Dosages vary by patient weight, age, and condition. Extended-release tablets should be swallowed whole without crushing or chewing. Grapefruit juice may inhibit Nifedipine metabolism and should be avoided during treatment. Regular monitoring of blood pressure and heart rate is essential during dose titration.

⚠️ Side Effects

Common Side Effects (>10% of patients)

  • Headache: Occurs in 15-20% of patients, often during initial therapy and typically resolves with continued use
  • Flushing: Facial and neck flushing due to rapid vasodilation, more common with immediate-release formulations
  • Peripheral edema: Ankle and foot swelling due to preferential vasodilation of peripheral vessels without corresponding venoconstriction
  • Dizziness and lightheadedness: Results from rapid blood pressure reduction, particularly with dose initiation
  • Palpitations: Reflex tachycardia may occur as the body compensates for reduced blood pressure
  • Fatigue: General tiredness and weakness reported by approximately 12% of patients

Less Common Side Effects (1-10%)

  • Gastrointestinal disturbances: Nausea, constipation, or abdominal discomfort in 3-7% of patients
  • Tremor: Fine hand tremor occasionally reported during early treatment phases
  • Sleep disturbances: Insomnia or unusual dreams in select patient populations
  • Muscle cramps: Particularly in lower extremities during extended treatment
  • Tachycardia: Persistent elevated heart rate in some patients requiring dose adjustment

Rare but Serious Side Effects

  • Gingival hyperplasia: Overgrowth of gum tissue occurring in approximately 0.1% of patients, necessitating improved oral hygiene and possible medication adjustment
  • Myocardial infarction: Rare but serious risk, particularly with rapid-acting immediate-release formulations in unstable angina patients
  • Acute hypotension: Severe blood pressure drop requiring immediate medical intervention in susceptible individuals

🔄 Drug Interactions

Nifedipine undergoes extensive hepatic metabolism through the cytochrome P450 enzyme system, particularly CYP3A4, making it susceptible to numerous clinically significant drug interactions. Concurrent medications that inhibit or induce these enzymes can substantially alter Nifedipine plasma concentrations and therapeutic effects. Patient education regarding potential interactions and regular medication review are essential components of safe therapy.

  • Grapefruit and grapefruit juice: Potently inhibit CYP3A4, significantly increasing Nifedipine plasma levels and toxicity risk; consumption should be avoided entirely
  • Cimetidine and ranitidine: H2-receptor antagonists that inhibit Nifedipine metabolism, potentially increasing drug levels and adverse effects
  • Rifampin and phenytoin: Potent enzyme inducers that accelerate Nifedipine metabolism, reducing plasma concentrations and therapeutic efficacy
  • Beta-blockers: Concurrent use may cause excessive cardiac depression; combination requires careful monitoring of heart rate and cardiac output
  • ACE inhibitors and angiotensin receptor blockers: May cause additive hypotensive effects, requiring dose adjustment and blood pressure monitoring
  • NSAIDs: May reduce antihypertensive efficacy of Nifedipine and increase risk of renal dysfunction

🚫 Contraindications & Warnings

  • Cardiogenic shock or severe hypotension: Nifedipine is contraindicated in patients with systolic blood pressure below 90 mmHg or clinical evidence of cardiogenic shock
  • Severe aortic stenosis: May cause excessive afterload reduction and hemodynamic collapse in this patient population
  • Hypersensitivity reactions: Absolute contraindication in patients with documented allergy to Nifedipine or other dihydropyridines
  • Pregnancy considerations: While used off-label for preterm labor, Nifedipine requires careful risk-benefit assessment in pregnant patients, particularly during first trimester
  • Hepatic dysfunction: Severe liver disease significantly impairs Nifedipine metabolism; dose reduction is essential in cirrhotic patients
  • Unstable angina: Immediate-release formulations may paradoxically increase myocardial infarction risk in unstable angina; extended-release forms are preferred
Medical Disclaimer: This information is for educational purposes only. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Do not use this information to self-diagnose or self-treat any medical condition. Nifedipine requires proper medical supervision and regular monitoring.

❓ Frequently Asked Questions

Is Nifedipine safe for long-term use?

Yes, Nifedipine has an excellent safety profile for long-term use when properly monitored. Extensive clinical trials have demonstrated its safety and efficacy over decades of continuous therapy. However, regular medical follow-up is essential to assess blood pressure control, monitor for adverse effects, and adjust dosing as needed. Long-term use is associated with excellent cardiovascular outcomes in hypertensive and anginal patients when combined with appropriate lifestyle modifications and adherence to therapy.

Can Nifedipine be taken with food?

Extended-release Nifedipine formulations can be taken with or without food and should be swallowed whole without crushing, chewing, or splitting. However, immediate-release formulations may be affected by food intake. More importantly, grapefruit and grapefruit juice should be strictly avoided, as they significantly increase Nifedipine plasma concentrations. Some patients find taking the medication with a light meal helps minimize gastrointestinal side effects. Always follow your specific prescriber's instructions regarding meal timing.

What should I do if I miss a dose?

If you miss a dose of Nifedipine, take it as soon as you remember, unless it is almost time for your next scheduled dose. Never double the dose to make up for a missed dose. If you are unsure about missed dose management, contact your healthcare provider or pharmacist. Consistent dosing is important for maintaining steady blood pressure control, so using pill organizers or phone reminders can help prevent missed doses. For extended-release formulations, maintaining a regular dosing schedule is particularly important.

Contact us on WhatsApp

Chat with our support team instantly on WhatsApp.

WhatsApp Chat on WhatsApp